Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study

BACKGROUND: We aimed to assess the overall cardiovascular and metabolic effect of the switch to three different single tablet regimens (STRs) [tenofovir alafenamide/emtricitabine/rilpivirine (TAF/FTC/RPV), TAF/FTC/elvitegravir/cobi (TAF/FTC/EVG/cobi) and ABC/lamivudine/dolutegravir (ABC/3TC/DTG)] in...

Descripción completa

Detalles Bibliográficos
Autores principales: Giacomelli, Andrea, Conti, Federico, Pezzati, Laura, Oreni, Letizia, Ridolfo, Anna Lisa, Morena, Valentina, Bonazzetti, Cecilia, Pagani, Gabriele, Formenti, Tiziana, Galli, Massimo, Rusconi, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220746/
https://www.ncbi.nlm.nih.gov/pubmed/34157984
http://dx.doi.org/10.1186/s12879-021-06304-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220746/
https://www.ncbi.nlm.nih.gov/pubmed/34157984
http://dx.doi.org/10.1186/s12879-021-06304-3

Ejemplares similares